Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cannabinoids
Research
Artelo cannabinoid agonist holds its own against semaglutide
Artelo’s ART27.13 in combination with semaglutide, showed double the weight loss compared with semaglutide alone.
Marissa Russo
Sep 18, 2026 2:22pm
Corbus posts obesity data in area where Novo, Sanofi stumbled
Sep 14, 2026 10:07am
Mira seeks to buy Skny for obesity, smoking cessation asset
Mar 24, 2025 10:08am
Polyrizon pays $3M for license to SciSparc's CB2R agonist
Aug 19, 2024 5:27am
Novo Nordisk bets $1B on biotech buyout to grow obesity pipeline
Aug 10, 2023 6:30am
Fortrea inks deal with Incannex for sleep apnea drug trial
Jul 27, 2023 9:28am